1,1'-联苯基,2-乙基-5-甲氧基- | 24025-08-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌嗪基哌啶类
• 中文名称: 1,1'-联苯基,2-乙基-5-甲氧基-
• 英文名称: 2-Methyloctahydro-1H-pyrido[1,2-a]pyrazine
• 英文别名: 2-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine
• CAS: 24025-08-9
• 化学式: C₉H₁₈N₂
• 分子量: 154.25
• InChiKey: WGXIYIFYMGDZJY-UHFFFAOYSA-N

物化性质

• 沸点：
  205.9±8.0 °C(Predicted)
• 密度：
  1.00±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

文献信息

• COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
  申请人：Li Hui

  公开号：US20120028923A1

  公开（公告）日：2012-02-02

  Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.

  披露了公式I的化合物，含有它们的组合物，以及使用这些化合物和组合物治疗调节JAK途径或抑制JAK激酶，特别是JAK2和JAK3，具有治疗用途的条件的方法。还披露了制造这些化合物的方法。
• [EN] COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND AMINOPYRIDINE DERIVATIVES AS HPK1 INHIBITORS<br/>[FR] COMBINAISON DE VACCINS CONTRE LE VIRUS DE L'HÉPATITE B (VHB) ET DE DÉRIVÉS D'AMINOPYRIDINE EN TANT QU'INHIBITEURS DE HPK1
  申请人：JANSSEN SCIENCES IRELAND UNLIMITED CO

  公开号：WO2020255022A1

  公开（公告）日：2020-12-24

  Therapeutic combinations of hepatitis B virus (HBV) vaccines and HPK1 inhibitors are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations of HBV vaccines and HPK1 inhibitors are also described. Kits comprising the disclosed therapeutic combinations are also described.

  描述了乙型肝炎病毒（HBV）疫苗和HPK1抑制剂的治疗组合。还描述了利用所述的HBV疫苗和HPK1抑制剂的治疗组合诱导免疫应答或治疗HBV诱发疾病的方法，特别是在患有慢性HBV感染的个体中。还描述了包含所述治疗组合的试剂盒。
• 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
  申请人：Dunn Robert

  公开号：US20080200471A1

  公开（公告）日：2008-08-21

  The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R 1 —R 4 A, B, D, E, and G are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本公开提供了具有亲和力的化合物，其对5-HT6受体具有亲和力，其化学式为（I）： 其中R1-R4，A，B，D，E和G如本文所定义。该公开还涉及制备这种化合物的方法，含有这种化合物的组合物，以及这些化合物的使用方法。
• NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：FOULON Loic

  公开号：US20110059955A1

  公开（公告）日：2011-03-10

  The present invention relates to novel 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, to their preparation and to their therapeutic application. The compounds of the present invention correspond to the formula (I): in which the variables are as set forth in the specification. These compounds exhibit a strong affinity and a high selectivity for human arginine-vasopressin (AVP) V 1a receptors and some compounds additionally exhibit a strong affinity for AVP V 1b receptors.

  本发明涉及新颖的3-氨基烷基-1,3-二氢-2H-吲哚-2-酮衍生物，其制备以及其治疗应用。本发明的化合物对应于式(I)： 其中变量如规范中所述。这些化合物表现出对人类精氨酸加压素（AVP）V1a受体具有强亲和力和高选择性，而且一些化合物还表现出对AVP V1b受体具有强亲和力。
• [EN] AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS<br/>[FR] COMPOSÉS AMIDO-THIOPHÈNE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BÊTA-HSD1
  申请人：UNIV EDINBURGH

  公开号：WO2009074789A1

  公开（公告）日：2009-06-18

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. Formula (I).

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些酰胺噻吩化合物，其中包括抑制11β-羟基类固醇脱氢酶1（11β-HSD1）。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体外和体内抑制11β-羟基类固醇脱氢酶1；治疗通过抑制11β-羟基类固醇脱氢酶1而得到改善的疾病；治疗代谢综合征，其中包括2型糖尿病和肥胖等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质紊乱和心血管疾病，如缺血性（冠状）心脏病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。公式（I）。